Bristol-Myers SquibbUS1101221083BMYBMY
Financials
Market Cap
$99.03B5Y beta
0.41EPS (TTM)
$3.858Free Float
2.02BP/E ratio (TTM)
12.67Revenue (TTM)
$45.01BEBITDA (TTM)
$20.63BFree Cashflow (TTM)
$7.91BPricing
Analyst Ratings
The price target is $55.75 and the stock is covered by 25 analysts.
Buy
6
Hold
18
Sell
1
Information
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.